Bartlett & Co’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Bartlett & Co’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-550	Closed	–	–	1215
2020 Q4	$0	Hold	550	–	–	﹤0.01%	1212
2020 Q3	$1K	Hold	550	–	–	﹤0.01%	820
2020 Q2	$2K	Hold	550	–	–	﹤0.01%	796
2020 Q1	$2K	Buy	+550	New	+$1.81K	﹤0.01%	788

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.82B AUM

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Bartlett & Co's BMY.RT Position: Q1 2021 in Review

Bartlett & Co sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 550 shares.

Bartlett & Co first reported a position in BMY.RT in Q1 2020 and held it in 4 quarters. The position peaked at $2K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Bartlett & Co reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Bartlett & Co sold 550 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
Bartlett & Co first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q1 2020 and held it in 4 quarters.
Bartlett & Co's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $2K in Q2 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Bartlett & Co's 13F filing for Q1 2021, filed 19 Apr 2021.